ArticleRNA (New York, N.Y.)2026
A method of comprehensive sequencing analysis of the small RNA fragmentome (RiboMarker).
Article in RNA (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
Small RNAs and RNA fragments (sRNAs) found in blood and other biofluids have emerged as promising biomarkers for cancer and other pathologies. Sequencing analysis of sRNAs representing the entire RNA fragmentome could improve understanding of their roles in cancer development and be used for discovery of new biomarkers, cancer detection, and personalized treatment management. Conventional methods of sRNA-seq library preparation are limited to detection of sRNAs with 5'-P and 3'-OH ends (sRNA Type 1) that represent only ∼10% of the whole RNA fragmentome, whereas sRNA Types having other termini are hidden. Although recently developed sRNA-seq methods provide detection of some or all hidden sRNAs, these methods cannot both detect all and distinguish between sRNAs of different RNA Types. Here we describe the RiboMarker approach for preparation of sRNA sequencing libraries that addresses these shortcomings. It uses distinctive enzymatic pretreatment(s) providing conversion between the RNA termini that can enrich for or deplete specific sRNA type(s) upfront of the universal method of library preparation. To monitor the efficacy of these pretreatments, we leveraged a pool of synthetic RNAs of different RNA Types and lengths spiked in brain or plasma RNA samples. This allows identification and analysis of relative abundance, sequencing profiles, and RNA Types of naturally occurring sRNAs representing different RNA classes. Using the RiboMarker approach, we demonstrated its capability to enhance the capacity and sensitivity of distinguishing between plasma RNA samples from different donors (simulating healthy individuals and cancer patients) by selecting and using sRNAs of specific RNA Type(s).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.